IMMUNOPRECISE ANTIBODIES LTD's ticker is IPA and the CUSIP is 45257F200. A total of 29 filers reported holding IMMUNOPRECISE ANTIBODIES LTD in Q3 2021. The put-call ratio across all filers is 0.55 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,882 | -40.0% | 1,028,253 | -3.0% | 0.09% | -39.3% |
| Q2 2023 | $3,138 | +7.1% | 1,060,055 | +0.2% | 0.15% | -0.7% |
| Q1 2023 | $2,931 | -42.0% | 1,058,035 | +9.1% | 0.15% | -45.1% |
| Q4 2022 | $5,054 | -99.9% | 970,147 | +0.3% | 0.28% | +27.9% |
| Q3 2022 | $3,859,000 | +8.1% | 967,090 | +2.9% | 0.22% | +15.0% |
| Q2 2022 | $3,570,000 | -25.5% | 939,475 | +0.8% | 0.19% | -12.6% |
| Q1 2022 | $4,792,000 | +9.0% | 932,200 | +13.6% | 0.21% | +8.1% |
| Q4 2021 | $4,397,000 | +13.8% | 820,258 | +32.0% | 0.20% | +11.9% |
| Q3 2021 | $3,865,000 | +6.9% | 621,447 | +3.4% | 0.18% | +9.9% |
| Q2 2021 | $3,617,000 | -28.8% | 600,810 | +16.2% | 0.16% | -32.1% |
| Q1 2021 | $5,079,000 | -14.3% | 517,195 | +30.5% | 0.24% | -19.1% |
| Q4 2020 | $5,927,000 | – | 396,425 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INGALLS & SNYDER LLC | 396,425 | $5,927,000 | 0.29% |
| Gradient Capital Advisors, LLC | 21,718 | $325,000 | 0.18% |
| Hillsdale Investment Management Inc. | 15,200 | $232,000 | 0.02% |
| Orion Portfolio Solutions, LLC | 15,821 | $237,000 | 0.01% |
| IFP Advisors, Inc | 1,960 | $30,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 300 | $4,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| CITIGROUP INC | 7 | $0 | 0.00% |
| MORGAN STANLEY | 2,100 | $31,000 | 0.00% |
| BANK OF MONTREAL /CAN/ | 5,900 | $98,000 | 0.00% |